Daily Stock Analysis, PTIE, Pain Therapeutics Inc, priceseries

Pain Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
1.19
Close
1.24
High
1.27
Low
1.18
Previous Close
1.07
Daily Price Gain
0.17
YTD High
1.37
YTD High Date
Mar 18, 2019
YTD Low
0.84
YTD Low Date
Jan 2, 2019
YTD Price Change
0.32
YTD Gain
34.42%
52 Week High
10.87
52 Week High Date
May 17, 2018
52 Week Low
0.76
52 Week Low Date
Dec 26, 2018
52 Week Price Change
-7.00
52 Week Gain
-84.95%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 6. 2017
6.30
Apr 7. 2017
6.86
1 Trading Days
8.89%
Link
LONG
Sep 13. 2017
3.40
Oct 3. 2017
3.95
14 Trading Days
16.18%
Link
LONG
Dec 12. 2017
4.21
Dec 14. 2017
4.48
2 Trading Days
6.41%
Link
LONG
Jan 8. 2018
4.45
Jan 25. 2018
7.53
12 Trading Days
69.17%
Link
LONG
Feb 28. 2018
6.50
Mar 15. 2018
6.91
11 Trading Days
6.34%
Link
LONG
May 15. 2018
9.18
May 24. 2018
9.68
7 Trading Days
5.40%
Link
LONG
Jan 4. 2019
0.99
Feb 5. 2019
1.11
21 Trading Days
11.85%
Link
Company Information
Stock Symbol
PTIE
Exchange
NasdaqGS
Company URL
http://www.paintrials.com
Company Phone
512-501-2444
CEO
Remi Barbier
Headquarters
Texas
Business Address
7801 N CAPITAL OF TEXAS HIGHWAY, SUITE 260, AUSTIN, TX 78731
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001069530
About

Pain Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of novel drugs. Its drug candidate includes REMOXY, which is a strong painkiller with a unique formulation designed to reduce potential risks of unintended use. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Description

Pain Therapeutics, Inc., a biopharmaceutical company, develops drugs for treating nervous system in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone for pain relief. It also develops FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; and PTI-125, a small molecule drug candidate to treat Alzheimer's disease and other neurological disorders. The company was founded in 1998 and is based in Austin, Texas.